{"id":54261,"date":"2026-01-15T22:05:37","date_gmt":"2026-01-15T14:05:37","guid":{"rendered":"https:\/\/flcube.com\/?p=54261"},"modified":"2026-01-15T22:05:39","modified_gmt":"2026-01-15T14:05:39","slug":"fosun-kairos-secures-greater-china-rights-to-elpasbios-allojoin-for-knee-osteoarthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54261","title":{"rendered":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis"},"content":{"rendered":"\n<p><strong>Fosun Kairos<\/strong>, a joint venture between <strong>Fosun Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) and <strong>Gilead Sciences\/Kite Pharma<\/strong>, announced a collaboration agreement with <strong>ElpasBio Holdings<\/strong> (spin\u2011off from AbelZeta Pharma) to obtain <strong>commercialization rights<\/strong> for <strong>AlloJoin (lotazadromcel)<\/strong>, an <strong>allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy<\/strong> for <strong>knee osteoarthritis (KOA)<\/strong>, in <strong>Mainland China, Hong Kong SAR, and Macau SAR<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>Fosun Kairos (Fosun Pharma &amp; Gilead\/Kite JV)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>ElpasBio Holdings (AbelZeta Pharma spin\u2011off)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AlloJoin (lotazadromcel)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Allogeneic haMPC therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Knee osteoarthritis (KOA)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China, Hong Kong SAR, Macau SAR<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Commercialization rights<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase\u202fIII (Phase\u202fI\/II completed)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> AlloJoin is an <strong>allogeneic mesenchymal stem cell (MSC) therapy<\/strong> that:<\/li>\n\n\n\n<li><strong>Suppresses inflammatory responses<\/strong> in the chronic inflammatory microenvironment of joints<\/li>\n\n\n\n<li><strong>Aids in repairing damaged cartilage<\/strong><\/li>\n\n\n\n<li><strong>Addresses functional issues<\/strong> caused by structural damage<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Intra\u2011articular injection<\/strong> directly into the knee joint<\/li>\n\n\n\n<li><strong>Clinical Evidence:<\/strong> Phase\u202fI and Phase\u202fII studies demonstrated <strong>favorable safety<\/strong> and <strong>significant efficacy<\/strong>; Phase\u202fIII trial ongoing<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> <strong>Off\u2011the\u2011shelf allogeneic<\/strong> MSC product eliminates need for autologous cell harvesting, reducing treatment time and cost<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China (Greater China)<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Knee Osteoarthritis Patients<\/strong><\/td><td>120\u202fmillion<\/td><td>300\u202fmillion<\/td><\/tr><tr><td><strong>Moderate\u2011to\u2011Severe KOA (Stage\u202fIII\/IV)<\/strong><\/td><td>36\u202fmillion<\/td><td>90\u202fmillion<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>12\u202fmillion<\/td><td>30\u202fmillion<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>NSAIDs, corticosteroids, hyaluronic acid (symptomatic only)<\/td><td><\/td><\/tr><tr><td><strong>Cell Therapy Penetration<\/strong><\/td><td>&lt;1\u202f%<\/td><td>&lt;1\u202f%<\/td><\/tr><tr><td><strong>Potential Annual Cost (USD)<\/strong><\/td><td>$8,000\u201112,000<\/td><td>$15,000\u201125,000<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>$96\u202fbillion<\/td><td>$450\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CartiHeal<\/strong> (Israel) \u2013 Agili\u2011C implant for cartilage regeneration (Phase\u202fIII, US)<\/li>\n\n\n\n<li><strong>Vericel<\/strong> (US) \u2013 MACI autologous chondrocyte implantation (approved, US\/EU)<\/li>\n\n\n\n<li><strong>CiMF<\/strong> (China) \u2013 Autologous MSC therapy for KOA (Phase\u202fII)<\/li>\n\n\n\n<li><strong>AlloJoin<\/strong> \u2013 <strong>First allogeneic MSC therapy<\/strong> for KOA in China; <strong>Phase\u202fIII\u2011ready<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Fosun Kairos will leverage its <strong>Shanghai cell therapy facility<\/strong> (capacity 10,000 doses\/year) for AlloJoin production; <strong>GMP certification<\/strong> expected Q4\u202f2026<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> Existing <strong>500\u2011person autoimmune sales force<\/strong> targeting tier\u20112\/3 hospitals; KOA market access team to be expanded by 200 reps in 2027<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202fIII completion:<\/strong> Q3\u202f2026<\/li>\n\n\n\n<li><strong>NDA submission to NMPA:<\/strong> Q1\u202f2027<\/li>\n\n\n\n<li><strong>Potential launch:<\/strong> Q4\u202f2027 (China)<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> ElpasBio retains <strong>ex\u2011China rights<\/strong>; potential <strong>US\/EU licensing<\/strong> upon Phase\u202fIII success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory approvals, and market penetration for AlloJoin. Actual results may differ due to clinical trial outcomes, competitive dynamics, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,4370,159,226,893,1568,892],"class_list":["post-54261","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-fosun-kairos","tag-fosun-pharmaceutical","tag-gilead-sciences","tag-hkg-2196","tag-kite-pharma","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54261\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis\" \/>\n<meta property=\"og:description\" content=\"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54261\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:05:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T14:05:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis\",\"datePublished\":\"2026-01-15T14:05:37+00:00\",\"dateModified\":\"2026-01-15T14:05:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Fosun Kairos\",\"Fosun Pharmaceutical\",\"Gilead Sciences\",\"HKG: 2196\",\"Kite Pharma\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54261#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54261\",\"name\":\"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:05:37+00:00\",\"dateModified\":\"2026-01-15T14:05:39+00:00\",\"description\":\"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\\\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54261\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54261#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54261","og_locale":"en_US","og_type":"article","og_title":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis","og_description":"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.","og_url":"https:\/\/flcube.com\/?p=54261","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:05:37+00:00","article_modified_time":"2026-01-15T14:05:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54261#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54261"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis","datePublished":"2026-01-15T14:05:37+00:00","dateModified":"2026-01-15T14:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54261"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Fosun Kairos","Fosun Pharmaceutical","Gilead Sciences","HKG: 2196","Kite Pharma","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54261#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54261","url":"https:\/\/flcube.com\/?p=54261","name":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:05:37+00:00","dateModified":"2026-01-15T14:05:39+00:00","description":"Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences\/Kite Pharma, announced a collaboration agreement with ElpasBio Holdings (spin\u2011off from AbelZeta Pharma) to obtain commercialization rights for AlloJoin (lotazadromcel), an allogeneic human adipose\u2011derived mesenchymal stem cell (haMPC) therapy for knee osteoarthritis (KOA), in Mainland China, Hong Kong SAR, and Macau SAR.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54261#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54261"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54261#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Kairos Secures Greater China Rights to ElpasBio\u2019s AlloJoin for Knee Osteoarthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54261"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54261\/revisions"}],"predecessor-version":[{"id":54265,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54261\/revisions\/54265"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}